Kura Oncology Inc (KURA) - News Archive

In recent developments within the pharmaceutical landscape, Kura Oncology and Kyowa Kirin s announcement of the FDA approval for KOMZIFTI (ziftomenib) marks a transformative moment for patients grappling with relapsed o...

Kura Oncology, a biopharmaceutical company specializing in oncology therapies, has recently presented promising data from its Farnesyl Transferase Inhibitor (FTI) programs at the 2025 European Society for Medical Oncolo...

In a series of pivotal publications and presentations, Kura Oncology, Inc. and Kyowa Kirin unveiled compelling data demonstrating the clinical efficacy of ziftomenib, a breakthrough therapeutic candidate, in various set...

Kura Oncology Faces Market Challenges Despite Advancements in Farnesyl Transferase Inhibitor Program Kura Oncology Inc. is poised to showcase significant advancements in its Farnesyl Transferase Inhibitor (FTI) program...

In the rapidly evolving landscape of oncology treatment, Kura Oncology Inc. in collaboration with Kyowa Kirin Co. is making significant strides with its pioneering drug, ziftomenib. At the prestigious 2025 ASCO Annual M...

Kura Oncology and Kyowa Kirin recently captivated the healthcare community by announcing the FDA’s acceptance and priority review of their New Drug Application (NDA) for Ziftomenib in treating adults with relapsed or re...

Kura Oncology Embraces Workforce Expansion and Precision Medicine Commitment with Strategic Inducement GrantsSAN DIEGO Kura Oncology, Inc. a trailblazer in the field of precision medicine for cancer treatment, reaffirme...

In an era where personalized medicine is increasingly becoming a focal point in the fight against cancer, Kura Oncology, Inc. a clinical-stage biopharmaceutical company based in San Diego, is making strides that could r...

Kura Oncology and Kyowa Kirin have entered into a significant global strategic collaboration focused on the development and commercialization of Ziftomenib, a novel therapeutic agent targeting acute leukemias. This coll...

Acute Myeloid Leukemia (AML) presents a significant clinical challenge due to its heterogeneous nature and the varied response to standard treatment protocols. Ziftomenib, a novel therapeutic agent, has garnered attenti...

Unlocking Hope: Kura Oncology s Ziftomenib Phase 1 Breakthrough in Treating Acute Myeloid Leukemia Published in The Lancet Oncology In the evolving landscape of oncology, where innovation and research intertwine, Kura O...

In a significant advancement for the treatment of advanced gastrointestinal stromal tumors (GISTs), Kura Oncology has announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND)...

Kura Oncology, Inc. (Nasdaq: KURA), a leading clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment, continues to demonstrate its commitment to growth and innovation. I...

In a groundbreaking development, Kura Oncology has reported preclinical data that highlights the potential of their menin inhibitor, Ziftomenib, in the treatment of type 2 diabetes. This article aims to provide an analy...

San Diego-based biopharmaceutical firm, Kura Oncology, Inc., recently announced the granting of inducement awards to eight new employees. The company s Compensation Committee approved the issuance of nonstatutory stock...

Combining KO-2806 and Cabozantinib Shows Promise in Renal Cell Carcinoma Treatment, Upcoming Trials to Test KO-2806 with Adagrasib in KRAS G12C-Mutant NSCLCRenal cell carcinoma (RCC) and non-small cell lung cancer (NSCL...

Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, recently announced the granting of inducement awards to two new employees. The Compensation Committee...

Kura Oncology Takes Promising Step Forward in Combating Acute Myeloid Leukemia In a groundbreaking development, Kura Oncology has administered the first patient with a potentially life-changing drug, ziftomenib, as part...

In the latest press release, Kura Oncology, a leading clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, announced the granting of inducement awards to three new emp...

Kura Oncology Announces Oversubscribed $150 Million Private PlacementKura Oncology Inc, a leading precision medicines company, recently revealed that it has successfully closed an oversubscribed $150 million private pla...